SOURCE: Eisai Inc.

April 19, 2005 09:01 ET

Eisai Inc. and U.S. Pharmacist Seek Nominations for Fourth Annual hhc Pharmacy Recognition Awards

Eisai Inc. hhc (human health care) Pharmacy Recognition Award Acknowledges Pharmacists Serving Alzheimer's Disease Patients

TEANECK and BLOOMFIELD, NJ -- (MARKET WIRE) -- April 19, 2005 -- Eisai Inc. and U.S. Pharmacist today announced that they are soliciting nominations for the Fourth Annual hhc (human health care) Pharmacy Recognition Award, established to honor pharmacists who work in their practice settings to provide quality care and improve the lives of Alzheimer's patients and their loved ones.

In recognition of the contributions that pharmacists make, Eisai, the discoverer and developer of the number-one prescribed Alzheimer's medication worldwide, Aricept® (donepezil hydrochloride tablets), developed the award in conjunction with U.S. Pharmacist, a monthly journal that provides pharmacists with information relevant to contemporary pharmacy practice. The award is named for Eisai's human health care (hhc) mission -- to satisfy unmet medical needs and increase benefits to patients and their families.

Awards will be given in four categories -- community, institutional, managed care and long-term care -- to pharmacists who have implemented initiatives that have enhanced the quality of care of patients or have improved the competencies of caregivers and health care providers. Applications will be accepted through May 27, 2005, and winners will be announced in August 2005.

"Pharmacists play an invaluable role in the care of patients, especially those with serious, chronic illnesses like Alzheimer's," said Angele C. D'Angelo, vice president and Director of Accreditation for Jobson, the educational group that services U.S. Pharmacist. "We want to recognize those outstanding professionals who've gone above and beyond to make a positive impact on patients, families and, ultimately, their communities."

"As an informed, respected, healthcare resource, pharmacists are an important partner in the delivery of quality health care," said Lonnel Coats, president and chief operating officer of Eisai Inc. "The Eisai Inc. hhc Pharmacy Recognition Award underscores the invaluable contributions pharmacists make to the care and caregiving of Alzheimer's patients and their loved ones."

Eligible nominees must be registered pharmacists licensed to practice in one of four settings -- community, institutional, managed care or long-term care -- and must have been involved in education or disease state management of patients with Alzheimer's disease within the past 12 months. A nominee's participation in the initiative can be an individual effort or as a member of a team. Applicants may self-nominate or be nominated by their peers. A full description of the award and nomination criteria is provided in the program literature, which can be found at www.uspharmacist.com or www.eisai.com.

Award recipients will be selected from a pool of nominees reviewed by a panel of independent judges selected by U.S. Pharmacist. Each of the winners will receive a specially designed keepsake plaque, a two-page article published in a future issue (September through December 2005) of U.S. Pharmacist profiling the winner's contribution, a framed keepsake reprint of the article and an honorarium.

Applications and information are available through Eisai Inc., U.S. Pharmacist or online at www.eisai.com and www.uspharmacist.com. For more information about the Eisai Inc. human health care Pharmacy Recognition Award, please call Angele C. D'Angelo at Jobson Accreditation Services, (609) 409-5465, or Linda DaSilva, RPh, director, trade relations at Eisai Inc., (201) 287-2061. Award recipients will be announced in the August 2005 issue of U.S. Pharmacist.

Information About Aricept® (donepezil HCl tablets) Treatment in Alzheimer's disease

While there is no cure for Alzheimer's disease, medical treatments are available to manage symptoms of the disease. Once-a-day prescription Aricept® is indicated for mild to moderate Alzheimer's disease.

In a progressively degenerative disease such as Alzheimer's, improvement, stabilization, or a less-than-expected decline over time is considered a positive response to treatment. These types of responses have been observed in patients treated with Aricept® in clinical trials for Alzheimer's disease. Individual responses to treatment vary, and some patients may not respond.

Aricept® is well tolerated but may not be for everyone. Some people may have nausea, diarrhea, do not sleep well or vomit. Some people may have muscle cramps, feel very tired, or may not want to eat. In studies, these side effects were usually mild and went away over time. People at risk for stomach ulcers or who take certain other medicines should tell their doctors because serious stomach problems, such as bleeding, may get worse. Some people who take Aricept® may experience fainting.

Aricept® is the number one prescribed Alzheimer's disease therapy worldwide, with more than 1 billion patient days of Aricept® therapy sold. More than 1.7 million people in the United States alone have begun Aricept® therapy.

Aricept® is co-promoted in the United States by Eisai Inc. and Pfizer Inc, which are dedicated to advances in Alzheimer's therapy.

For more information about managing Alzheimer's disease and about Aricept®, and for prescribing information on Aricept®, please visit www.aricept.com.

About Eisai

Eisai Inc. is a US pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care company that discovers, develops and markets products in more than 30 countries. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business with sales of nearly $1.7 billion in fiscal year 2003 (year ending March 31, 2004).

Eisai Inc. employs more than 1,100 people at its headquarters in Teaneck, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in the field. Between 1998 and 2003, Eisai Inc. moved up rapidly in the rankings (based on revenues) of US pharmaceutical companies from No. 44 to 20.

About Pfizer Inc

Pfizer Inc discovers, develops, manufactures and markets leading prescription medicines for humans and animals and many of the world's best-known consumer brands.

About U.S. Pharmacist U.S. Pharmacist is a monthly journal dedicated to providing the nation's pharmacists with up-to-date, authoritative, peer-reviewed clinical articles relevant to contemporary pharmacy practice in a variety of settings, including community pharmacy, hospitals, managed care systems, ambulatory care clinics, home care organizations, long-term care facilities, industry and academia. The publication is also useful to pharmacy technicians, students, other health professionals and individuals interested in health management.

Contact Information

  • Contacts:
    Cathy Pollini
    Eisai Inc.
    201-287-2052

    Harold E. Cohen, RPh
    U.S. Pharmacist
    973-954-9223

    Julia Lamm
    Hill & Knowlton
    212-885-0413